title: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
abstract: There is evidence of the clinical efficacy and safety of clomipramine and the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of obsessive-compulsive disorder (OCD). In the present study, we have compared the efficacy and safety of 40 mg/day of fluoxetine and 150 mg/day of clomipramine in patients with OCD, diagnosed according to DSM-IIIR. A total of 55 patients entered this 8-week, double-blind controlled study. Efficacy for both drugs was comparable. The primary efficacy criterion, the Y-BOCS Total score, did not show any significant differences between treatment arms. Response rate was higher with clomipramine, using a 25% decrease in Y-BOCS Total score as response threshold, but there were no significant differences between treatment arms using a 35% threshold. Overall safety and tolerability were good for both drugs, being slightly better for fluoxetine.
authors.affiliation: Hospital Universitario San Carlos, Madrid, Spain.
authors.forename: J J
authors.initials: JJ
authors.lastname: López-Ibor
authors.forename: J
authors.initials: J
authors.lastname: Saiz
authors.forename: J
authors.initials: J
authors.lastname: Cottraux
authors.forename: I
authors.initials: I
authors.lastname: Note
authors.forename: R
authors.initials: R
authors.lastname: Viñas
authors.forename: M
authors.initials: M
authors.lastname: Bourgeois
authors.forename: M
authors.initials: M
authors.lastname: Hernández
authors.forename: J C
authors.initials: JC
authors.lastname: Gómez-Pérez
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D002997:Clomipramine; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors